Biomedical ChromatographyVolume 8, Issue 5 p. 251-254 Article Determination of flutamide and hydroxyflutamide in dog plasma by a sensitive high performance liquid chromatography method utilizing mid-bore chromatography Don Farthing, Don Farthing Division of Clinical Pharmacology and Hypertension, Medical College of Virginia, Virginia Commonwealth University, Richmond, VA, USASearch for more papers by this authorDomenic Sica, Corresponding Author Domenic Sica Division of Clinical Pharmacology and Hypertension, Medical College of Virginia, Virginia Commonwealth University, Richmond, VA, USADivision of Clinical Pharmacology and Hypertension, Medical College of Virginia, Virginia Commonwealth University, Richmond, VA, USASearch for more papers by this authorItaf Fakhry, Itaf Fakhry Division of Clinical Pharmacology and Hypertension, Medical College of Virginia, Virginia Commonwealth University, Richmond, VA, USASearch for more papers by this authorDenise Lowe Walters, Denise Lowe Walters Whitby Research Inc., Richmond, VA, USASearch for more papers by this authorEugenio A. Cefali, Eugenio A. Cefali Whitby Research Inc., Richmond, VA, USASearch for more papers by this authorGeoffrey Allan, Geoffrey Allan Whitby Research Inc., Richmond, VA, USASearch for more papers by this author Don Farthing, Don Farthing Division of Clinical Pharmacology and Hypertension, Medical College of Virginia, Virginia Commonwealth University, Richmond, VA, USASearch for more papers by this authorDomenic Sica, Corresponding Author Domenic Sica Division of Clinical Pharmacology and Hypertension, Medical College of Virginia, Virginia Commonwealth University, Richmond, VA, USADivision of Clinical Pharmacology and Hypertension, Medical College of Virginia, Virginia Commonwealth University, Richmond, VA, USASearch for more papers by this authorItaf Fakhry, Itaf Fakhry Division of Clinical Pharmacology and Hypertension, Medical College of Virginia, Virginia Commonwealth University, Richmond, VA, USASearch for more papers by this authorDenise Lowe Walters, Denise Lowe Walters Whitby Research Inc., Richmond, VA, USASearch for more papers by this authorEugenio A. Cefali, Eugenio A. Cefali Whitby Research Inc., Richmond, VA, USASearch for more papers by this authorGeoffrey Allan, Geoffrey Allan Whitby Research Inc., Richmond, VA, USASearch for more papers by this author First published: September/October 1994 https://doi.org/10.1002/bmc.1130080511Citations: 25AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinkedInRedditWechat Citing Literature Volume8, Issue5September/October 1994Pages 251-254 RelatedInformation

This study compared the pharmacokinetics of flurbiprofen (F) and three major metabolites in patients with end‐stage renal disease (ESRD) undergoing continuous ambulatory peritoneal dialysis (CAPD) with the pharmacokinetics of F in normal subjects. A single 100‐mg dose of F was administered to each of nine normal subjects and eight ESRD subjects. Blood and urine samples were collected in both groups; serial and end of dwell dialysate samples were obtained from the ESRD subjects. Plasma was analyzed for both the R and S optical isomers of F and its major metabolite, 4′‐hydroxy‐flurbiprofen (HF). Urine and dialysate were analyzed for F and three known metabolites. Plasma concentrations of F in the ESRD subjects were approximately 50% of the values obtained from the normal subjects (P < .05). Flurbiprofen half‐life and Tmax were not different. Elimination of HF was reduced in ESRD subjects. Urinary data suggest that HF was the major metabolite excreted (36% of the dose) in normal subjects whereas 3′, 4′ ‐dihydroxy‐flurbiprofen was the major metabolite (9% of the dose) excreted in the ESRD group. Mean urinary recovery of the dose was 73% in the normal subjects, but only 16% in ESRD subjects. Neither F nor its metabolites were detected in dialysate. Small enantiomer differences were seen. This study suggests that ESRD subjects have lower plasma levels of F than normal subjects when administered equal size doses. Accumulation of metabolites may occur in ESRD subjects upon multiple dosing. Enantiomer differences are not clinically significant.

The single-dose pharmacokinetics of azlocillin and piperacillin were compared by using a randomized, crossover design. The concentrations of azlocillin in serum were consistently higher than those of piperacillin throughout an 8-h study. The area under the time-concentration curve of azlocillin was significantly greater than that of piperacillin, and the total body clearance of azlocillin was significantly lower than that of piperacillin.